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Infectious Disease

Risk for Clostridium difficile Infection After
Allogeneic Hematopoietic Cell Transplant
Remains Elevated in the Postengraftment Period
Erik R. Dubberke, MD, MSPH,1 Kimberly A. Reske, MPH,1 Margaret A. Olsen, PhD, MPH,1
Kerry M. Bommarito, PhD, MPH,1 Sondra Seiler, BA,1 Fernanda P. Silveira, MD, MS,2 Tom M. Chiller, MD, MPHTM,3
John DiPersio, MD,4 Victoria J. Fraser, MD1

Background. Clostridium difficile infection (CDI) is a frequent cause of diarrhea among allogeneic hematopoietic cell transplant
(HCT) recipients. It is unknown whether risk factors for CDI vary by time posttransplant. Methods. We performed a 3-year pro-

spective cohort study of CDI in allogeneic HCTrecipients. Participants were enrolled during their transplant hospitalizations. Clinical
assessments were performed weekly during hospitalizations and for 12 weeks posttransplant, and monthly for 30 months thereafter. Data were collected through patient interviews and chart review, and included CDI diagnosis, demographics, transplant characteristics, medications, infections, and outcomes. CDI cases were included if they occurred within 1 year of HCT and were
stratified by time from transplant. Multivariable logistic regression was used to determine risk factors for CDI. Results. One hundred eighty-seven allogeneic HCT recipients were enrolled, including 63 (34%) patients who developed CDI. 38 (60%) CDI cases
occurred during the preengraftment period (days 0-30 post-HCT) and 25 (40%) postengraftment (day >30). Lack of any
preexisting comorbid disease was significantly associated with lower risk of CDI preengraftment (odds ratio [OR], 0.3; 95% confidence interval [CI], 0.1-0.9). Relapsed underlying disease (OR, 6.7; 95% CI, 1.3-33.1), receipt of any high-risk antimicrobials (OR,
11.8; 95% CI, 2.9-47.8), and graft-versus-host disease (OR, 7.8; 95% CI, 2.0-30.2) were significant independent risk factors for
CDI postengraftment. Conclusions. A large portion of CDI cases occurred during the postengraftment period in allogeneic HCT
recipients, suggesting that surveillance for CDI should continue beyond the transplant hospitalization and preengraftment period.
Patients with continued high underlying severity of illness were at increased risk of CDI postengraftment.
(Transplantation Direct 2017;3: e145; doi: 10.1097/TXD.0000000000000662. Published online 17 March, 2017.)

C

lostridium difficile infection (CDI) is a common infectious complication of allogeneic hematopoietic cell
transplantation (HCT), but the epidemiology, risk factors,
and outcomes of CDI in these patients are poorly understood.
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Estimates of CDI incidence among allogeneic HCT recipients
vary widely, with an upper range of approximately 30%.1-9
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Many studies of CDI in this patient population are limited to
autologous HCT recipients10-13; other studies combine allogeneic and autologous HCT recipients1,4,14-16 and such combined study results may not be applicable to allogeneic HCT
recipients alone. Incidence rates and time from transplant to
CDI may be different between autologous and allogeneic
transplant recipients,1,17,18 possibly because of differences in
immunosuppression, underlying severity of illness, or antimicrobial exposures between these 2 transplant populations.
Risk factors for CDI specific to HCT patients have proven
difficult to identify, likely because of study design limitations
and the ubiquity of traditional CDI risk factors among allogeneic HCT recipients. Several prior studies have evaluated
CDI risk factors specifically in allogeneic HCT recipients.3,5-7,9,18,19 All of these studies were retrospective and
most were limited to risk factor data collected during inpatient
hospitalizations. We previously performed a retrospective
study of CDI in allogeneic HCT at Barnes-Jewish Hospital
(BJH), and identified third-/fourth-generation cephalosporins,
diabetes, and preengraftment state as risk factors for CDI.19
Risk factors for CDI identified in other studies of HCT recipients include carbapenem use, myeloablative conditioning, and
T-cell depletion.2,6,18
Most previous studies of CDI in allogeneic HCT patients
have focused on the preengraftment period, but some studies
have reported a median time from transplant to CDI longer
than 30 days; thus, focusing on the preengraftment period
may miss a significant portion of CDI cases.1,3 Furthermore,
the ubiquity of traditional CDI risk factors among HCT patients during the preengraftment period might have limited
identification of risk factors in previously published studies,
and specific risk factors for CDI may differ by time from transplant. No studies have examined the characteristics of and risk
factors for CDI among allogeneic HCT recipients stratified by
time from transplant. A better understanding of the epidemiology of CDI is needed to prevent CDI in this highly susceptible
population. The purpose of this study was to evaluate risk factors for and outcomes of CDI in allogeneic HCT recipients,
using a prospective study design that included outpatient assessments, stratified by time from transplant.
MATERIALS AND METHODS
Study Design

This cohort study was conducted at Siteman Cancer Center,
the NCI designated comprehensive Cancer Center of BJH, a
1250-bed, tertiary care facility in St. Louis, Missouri. The
study was performed in conjunction with the Organ Transplant Infection Prevention and Detection Project (OTIP) of
the Centers for Disease Control and Prevention. OTIP was a
prospective cohort study of infections in patients undergoing
allogeneic HCT or lung transplant. At BJH, only allogeneic
HCT recipients were enrolled in the OTIP study, and specific
additional data related to CDI were collected at BJH, as described below. The study dates were April 2007 to March
2010. During the study period, the HCT ward at BJH did
not have a required neutropenic fever prophylaxis protocol,
and cefepime was the preferred agent for neutropenic fever.
Study participants were approached to participate after admission for their allogeneic HCT hospitalization. An assessment
of each participant was performed at enrollment and weekly
during each hospitalization. After discharge, participants were
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contacted by phone weekly for up to 12 weeks posttransplant.
After 12 weeks, participants were contacted monthly for
30 months post-HCT. If participants were readmitted to the
hospital, they were followed up weekly until discharge. Seven
participants had >1 HCT during the study period; for these
participants, only the first HCT was included in analyses.
The Washington University Human Research Protection Office approved this study and written informed consent was
obtained from all participants.
Data Collection

Demographic data collected at study enrollment included
age, sex, race, underlying disease status at the time of transplant, comorbid diseases, type of allogeneic HCT conditioning,
prior chemotherapy/immunosuppressive therapies, and transplantation history. Comorbid diseases were defined as one for
which the patient was receiving treatment or medical consultation. Other data collected at the time of transplantation included transplant date and time, ongoing immunosuppressive
medications received, and laboratory culture and/or test results.
The weekly inpatient and outpatient assessments included patient status (home, inpatient, ICU, deceased), mechanical ventilation, current medications, and symptoms of infection. All
infections were reviewed by an infectious diseases physician
(E.R.D.) to determine whether the infection was probable,
confirmed, or neither. Infections were defined according to
National Nosocomial Infections Surveillance (NNIS) criteria
(now National Healthcare Safety Network).20 Graft-versus-host
disease (GVHD) was scored according to the Glucksberg
criteria.21 In addition to interviews, clinical data were collected
prospectively from medical records when participants were
hospitalized and as available from outpatient clinic records.
CDI-Specific Data Collection

CDI was defined as a positive toxin assay for C. difficile
plus clinical symptoms consistent with CDI. Positive C. difficile toxin assay results from the BJH laboratory were collected
as part of the ongoing assessments. The BJH laboratory used
a toxin CDI test for CDI diagnosis during the study period
(Remel Xpect C. difficile Toxin A/B, Lenexa, KS). CDIspecific data included: CDI onset date, method of diagnosis
(toxin, endoscopy, CT scan), presence of CDI symptoms (diarrhea, abdominal pain or distension, ileus, peritoneal signs,
fever, hypothermia, blood in stool, toxic megacolon), outcomes (duration of illness, colectomy or other surgery for
CDI, death due to CDI), and type of, duration of, and response to CDI therapy. Antimicrobial exposures before, during, and after CDI were collected. Prospectively collected
medication data were supplemented with data collected electronically from the hospital’s Medical Informatics database.
CDI cases were classified by severity (mild, moderate, severe)
according to modified Common Terminology Criteria for
Adverse Events (CTCAE) criteria; details of this classification
system have been published elsewhere.19,22
Data Analysis

Participants were excluded from analyses if they had a history of CDI within the previous 60 days and/or were still receiving antimicrobial treatment for CDI at the time of their
allogeneic HCT (n = 9). For CDI cases, the CDI diagnosis
date was considered the index date. For controls (all allogeneic HCT recipients who did not develop CDI), an index date
was randomly selected such that the distribution of time from

© 2017 Wolters Kluwer

TABLE 1.

TABLE 1. (Continued)

Symptoms, treatment, and outcomes of CDI in allogeneic
HCT recipients
Variable
CDI severitya
Mild
Moderate
Severe
Time from transplant to CDI (median days [range])
CDI 0-30 d posttransplant (preengraftment)
CDI 31-99 d posttransplant (postengraftment)
CDI 100-365 d posttransplant (postengraftment)
Diagnosis method
Toxin assay
Endoscopy
CT scan
Setting onset of CDI
Inpatient
Outpatient
If outpatient, admitted for CDI?
Classificationa
Healthcare onset, healthcare facility-associated
Community onset, healthcare facility-associated
Indeterminate
Symptoms
Diarrhea severity grade (maximum during illness)b
1
2
3
4
Ileus
Abdominal tenderness during CDI
Abdominal tenderness within 48 h of CDI diagnosis
Peritoneal signs
Peritoneal signs within 48 h of CDI diagnosis
Abdominal distension during CDI
Abdominal distension within 48 h of CDI diagnosis
Fever during CDI
Fever within 48 h of CDI diagnosis
Hypothermia during CDI
Hypothermia within 48 h of CDI diagnosis
Blood in stool during CDI
Blood in stool within 48 h of CDI diagnosis
Toxic megacolon
Surgery for CDI
Response to CDI therapy
Responded
Did not respond
Unknown
Duration of CDI (median days from symptom onset to
resolution of diarrhea [range])
Days from symptom onset to response to therapy
(median [range])
Days from symptom onset to diarrhea improvement
(median [range])
Duration of CDI antimicrobial treatment (median [range])
CDI antimicrobial treatment
Oral metronidazole alone

3

Dubberke et al

N = 63 with
CDI n (%)
32 (51)
14 (22)
17 (27)
23 (0-365)
38 (60)
11 (18)
14 (22)
63 (100)
1 (2)
3 (5)
54 (86)
9 (14)
9 (100)
50 (79)
9 (14)
4 (6)

26 (41)
19 (30)
11 (18)
7 (11)
0
18 (29)
7 (11)
1 (2)
0
18 (29)
8 (13)
34 (54)
27 (43)
13 (21)
4 (6)
3 (5)
2 (3)
0
0
61 (97)
1 (2)
1 (2)
6 (1-51)
5 (1-51)

Variable
Oral and IV metronidazole
Oral vancomycin alone
Oral vancomycin and oral metronidazole
Oral vancomycin and IV metronidazole
Oral metronidazole, IV metronidazole, and oral vancomycin
Oral metronidazole, IV metronidazole, oral vancomycin,
and intravenous immunoglobulin
Died within 180 d of CDI
Mild CDIc
Moderate CDIc
Severe CDIc
Preengraftment CDI (0-30 d posttransplant)d
Postengraftment CDI (31-365 d posttransplant)d
CDI recurrence within 56 d of index CDI

N = 63 with
CDI n (%)
6 (10)
2 (3)
5 (8)
3 (5)
9 (14)
1 (2)

12 (48)
6 (24)
7 (28)
15 (60)
10 (40)
5 (8)

a
Health care onset, healthcare facility associated = CDI diagnosis ≥48 hours after hospital admission;
Community onset, healthcare facility associated = CDI diagnosis as outpatient or <48 hours after admission with a discharge from a healthcare facility in the previous 4 weeks; Indeterminate = CDI diagnosis as outpatient or <48 hours after admission with a discharge from a healthcare facility in
the previous 4–12 weeks.28
b
Per modified CTCAE criteria.19,22
c
Log-rank P = 0.91; 38% of mild CDI died vs. 43% of moderate CDI and 26% of severe CDI.
d
Log-rank P = 0.75; 39% of preengraftment CDI died vs. 40% of postengraftment CDI.

allogeneic HCT to the index date was comparable between
cases and controls. Data analyses were stratified by time from
transplant to index date: 0 to 30 days posttransplant
(preengraftment), and 31 to 365 days posttransplant
(postengraftment). Only 2 CDI cases occurred more than
365 days posttransplant; these were considered outliers
and were excluded from analyses. Antimicrobials were classified into high risk and low risk categories based on risk of
causing CDI and our prior analysis. High risk antimicrobials included aminopenicillins/penicillins, cephalosporins, 8-methoxyfluoroquinolones, and clindamycin23;
all other antimicrobials were considered low risk. Data such
as medications were included if they occurred within the 30 days
before index date, including pretransplant exposures when applicable. Neutropenia within 48 hours before index date was included. Risk factors for CDI were evaluated using chi-square/
Fischer exact tests or univariate logistic regression, and logistic regression was used for multivariable analyses. Because of
small sample sizes, priority for inclusion of variables into the
models was based on clinical/biological plausibility, sufficient
sample size within the variable, and univariate analyses. Variables with zero cells on univariate analyses were excluded
from multivariable models. Due to the small sample size in
the postengraftment analyses, at most 3 variables could be included at a time in multivariable models to avoid over specification. Death within 180 days of CDI was compared by CDI
severity and time from transplant using the log-rank test. Analyses were performed with SPSS, version 21.0 (IBM Corp,
Armonk, NY) and SAS version 9.2 (SAS, Cary, NC).

4 (1-51)
17 (3-83)
37 (59)

RESULTS
Two hundred fifty-four allogeneic HCT patients were
approached to participate in the study; 199 consented to participate (78%), and 187 (74%) were included in analyses).
Of the 187 patients, 63 (34%) developed CDI within 1 year
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of HCT and 124 (66%) did not. CDI symptoms and antimicrobial treatment are described in Table 1. Nine (14%) cases
were diagnosed as outpatients. No participants required surgery for CDI. Ninety-seven percent of participants responded
to antimicrobial therapy, and the median time to resolution
of symptoms was 6 days. The majority of the CDI cases were
classified as mild (51%), followed by moderate (22%) and

severe (27%) according to the modified CTCAE criteria.
There were no significant differences in death within 180 days
post-CDI between mild, moderate, and severe CDI or between preengraftment (n = 38) and postengraftment CDI
(n = 25) (Table 1; P > 0.05 for all).
Thirty-eight (60% of total) cases of CDI were diagnosed
in the preengraftment period and 81 controls had their

TABLE 2.

Risk factors for CDI preengraftment (0-30 days after transplant) (N = 119): univariate analysis and multivariable logistic
regression model
Variables
Age, y
18-39
40-65
>65
Female
Comorbidities
Cardiovascular disease
Pulmonary disease
GI disease
Renal disease
Previous splenectomy
Diabetes
Autoimmune disease
HIV, HCV, HBV
Other comorbid disease
No comorbid disease
Neutropenic within 48 h of index date
Myeloablative conditioning
Related donor
Matched donor
Relapsed underlying diseasea
Hospitalized at index date
Medications in 30 d before index dateb
Any antimicrobials
Any high risk antimicrobials
Any low risk antimicrobials
Growth factors
Gastric acid suppressor
PPI
H2 blocker
Chemotherapy or total body irradiation
Narcotics
Insulin
Immunosuppressive/steroid
Infections within 30 d before index date
Any infection
BSIc
Pneumonia
Fungal infection
Viral infection
GVHD
Any GVHD before index date
Any GVHD within 7 d before index date
Gut GVHD within 7 d before index date
a

CDI cases n = 38 (n [%])

Controls n = 81 (n [%])

uOR (95% CI)

P

9 (24)
27 (71)
2 (5)
14 (37)

20 (25)
60 (74)
1 (1)
33 (41)

Reference
1.0 (0.4-2.5)
4.4 (0.4-55.6)
0.8 (0.4-1.9)

1.00
0.25
0.69

15 (40)
5 (13)
6 (16)
0 (0)
2 (5)
5 (13)
0
2 (5)
13 (34)
7 (18)
26 (68)
28 (74)
13 (34)
37 (97)
12 (32)
37 (98)

19 (24)
6 (7)
6 (7)
3 (4)
1 (1)
9 (11)
0
4 (5)
27 (33)
31 (38)
47 (58)
49 (61)
25 (31)
78 (96)
18 (22)
72 (89)

2.1 (0.9-4.9)
1.9 (0.5-6.6)
2.3 (0.7-7.8)
Undefined
4.4 (0.4-50.6)
1.2 (0.4-3.9)

0.07
0.33
0.16
0.55
0.24
0.77

1.1 (0.2-6.1)
1.0 (0.5-2.3)
0.4 (0.1-0.9)
1.6 (0.7-3.5)
1.8 (0.8-4.3)
1.2 (0.5-2.6)
1.4 (0.1-14.1)
1.6 (0.7-3.8)
4.6 (0.6-37.9)

1.00
0.93
0.03
0.28
0.16
0.72
1.00
0.27
0.17

35 (92)
27 (71)
27 (71)
17 (45)
37 (97)
16 (42)
35 (92)
36 (95)
20 (53)
7 (18)
38 (100)

65 (80)
50 (62)
55 (68)
34 (42)
80 (99)
36 (44)
76 (94)
79 (98)
42 (52)
16 (20)
81 (100)

2.9 (0.8-10.5)
1.5 (0.7-3.5)
1.2 (0.5-2.7)
1.1 (0.5-2.4)
0.5 (0.03-7.6)
0.9 (0.4-2.0)
0.8 (0.2-3.4)
0.5 (0.1-3.4)
1.0 (0.5-2.2)
0.9 (0.3-2.5)

0.12
0.32
0.73
0.78
0.54
0.81
0.71
0.59
0.94
0.86

14 (37)
3 (8)
2 (5)
1 (3)
7 (18)

34 (42)
9 (11)
3 (4)
0 (0)
7 (9)

0.8 (0.4-1.8)
0.7 (0.2-2.7)
1.4 (0.2-9.0)
Undefined
2.4 (0.8-7.4)

0.60
0.75
0.65
0.32
0.12

1 (3)
1 (3)
0

1 (1)
1 (1)
0

2.2 (0.1-35.5)
2.2 (0.1-35.5)

0.54
0.54

Relapsed disease status at the time of transplant.
Pretransplant medication exposures were included when applicable.
c
All met NNIS criteria.
aOR, adjusted OR; uOR, unadjusted OR; 95% CI, 95% confidence interval.
b

aOR (95% CI)

P

0.3 (0.1-0.9)

0.02

2.1 (0.9-5.0)

0.10

3.2 (0.8-12.0)

0.09
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randomly selected index date in this time period. Only lack of
any underlying comorbid disease was significantly associated
with CDI in univariable analysis (protective effect: odds ratio
[OR], 0.4; Table 2). Cardiovascular disease was marginally
associated with increased risk of CDI in univariable analysis (Table 2). In multivariable analysis, only lack of any
underlying comorbid disease was significantly associated with
lower risk of CDI (OR, 0.3), although there was a trend for
myeloablative conditioning and receipt of any antimicrobials

in the previous 30 days to be associated with increased risk
of CDI (Table 2).
There were 25 CDI cases in the postengraftment period,
and 43 controls had their randomly selected index date during that time (Table 3). Numerous risk factors for CDI were
identified in univariable analysis: neutropenia within 48 hours
before CDI/index, myeloablative conditioning, admitted at
index date, receipt of any antimicrobials, high risk antimicrobials,
low risk antimicrobials, gastric acid suppressor, proton pump

TABLE 3.

Risk factors for CDI postengraftment (>30 days posttransplant) (N = 68): univariate analysis and multivariable logistic
regression model
Variable
Age, y
18-39
40-65
>65
Female
Comorbidities
Cardiovascular disease
Pulmonary disease
GI disease
Renal disease
Splenectomy
Diabetes
Autoimmune disease
HIV, HCV, HBV
Other comorbid disease
No comorbid disease
Neutropenic within 48 h of index date
Myeloablative conditioning
Related donor
Matched donor
Relapsed diseasea
Admitted at index date
Medications in 30 d before index date
Any antimicrobials
Any high-risk antimicrobials
Any low-risk antimicrobials
Growth factors
Gastric acid suppressor
PPI
H2 blocker
Chemotherapy or total body irradiation
Narcotic
Insulin
Immunosuppressive/steroid
Infections in 30 d before index date
Any infection
BSIb
Pneumonia
Fungal infection
Viral infection
GVHD
Any GVHD before index date
Any GVHD within 7 d before index date
Gut GVHD within 7 d before index date
a
b

Relapsed disease status at the time of transplant.
All met NNIS criteria.

CDI cases n = 25 (n [%])

Controls n = 43 (n [%])

uOR (95% CI)

P-value

5 (20)
19 (76)
1 (4)
10 (40)

12 (28)
24 (56)
7 (16)
17 (40)

Reference
1.9 (0.6-6.3)
0.3 (0.03-3.6)
1.0 (0.4-2.8)

0.30
0.37
0.97

10 (40)
1 (4)
3 (12)
0
1 (4)
4 (16)
1 (4)
0 (0)
6 (24)
8 (32)
11 (44)
23 (92)
10 (40)
25 (100)
9 (36)
22 (88)

7 (16)
2 (5)
7 (16)
0
1 (2)
4 (9)
0 (0)
1 (2)
17 (40)
21 (49)
0 (0)
30 (70)
15 (35)
41 (95)
7 (16)
4 (9)

3.4 (1.1-10.7)
0.9 (0.1-9.9)
0.7 (0.2-3.0)

0.03
1.00
0.74

1.8 (0.1-29.3)
1.9 (0.4-8.2)
Undefined
Undefined
0.5 (0.2-1.5)
0.5 (0.2-1.4)
Undefined
5.0 (1.0-24.3)
1.2 (0.5-3.4)
Undefined
2.9 (0.9-9.1)
71.5 (14.6-349.1)

1.00
0.45
0.37
1.00
0.19
0.18
<0.01
0.04
0.67
0.53
0.07
<0.01

25 (100)
20 (80)
25 (100)
12 (48)
22 (88)
13 (52)
11 (44)
10 (40)
11 (44)
9 (36)
23 (92)

32 (74)
14 (33)
31 (72)
10 (23)
20 (47)
11 (26)
15 (35)
10 (23)
11 (26)
5 (12)
41 (95)

Undefined
8.3 (2.6-26.7)
Undefined
3.0 (1.1-8.8)
8.4 (2.2-32.4)
3.2 (1.1-8.9)
1.5 (0.5-4.0)
2.2 (0.8-6.4)
2.3 (0.8-6.5)
4.3 (1.2-14.8)
0.6 (0.1-4.3)

<0.01
<0.01
<0.01
0.04
<0.01
0.03
0.46
0.14
0.12
0.03
0.62

10 (40)
5 (20)
2 (8)
2 (8)
2 (8)

9 (21)
2 (5)
3 (7)
1 (2)
4 (9)

2.5 (0.9-7.5)
5.1 (0.9-28.8)
1.2 (0.2-7.5)
3.7 (0.3-42.5)
0.8 (0.1-5.0)

0.09
0.09
1.00
0.55
1.00

17 (68)
8 (32)
3 (12)

13 (30)
2 (5)
0 (0)

4.9 (1.7-14.2)
9.6 (1.9-50.2)
Undefined

<0.01
<0.01
0.05

aOR (95% CI)

P

6.7 (1.3-33.1)

0.02

11.8 (2.9-47.8)

<0.01

7.8 (2.0-30.2)

<0.01
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inhibitor (PPI), or insulin therapy in the previous 30 days,
any GVHD before the index date, any GVHD in the 7 days
before CDI/index date, and gut GVHD in the 7 days before
CDI/index date. Relapsed disease was associated with
marginally increased risk of CDI. The multivariable model
with best fit (Hosmer-Lemeshow P = 0.70) and strongest
clinical plausibility was receipt of high risk antimicrobials
(OR, 11.8), any GVHD before the index date (OR, 7.8),
and relapsed disease status at transplant (OR, 6.7).
DISCUSSION
This study is the first to compare risk factors for CDI in allogeneic HCT recipients during both the preengraftment and
postengraftment periods. This was done because these are
well defined periods of risk for infections post-HCT. The results of this study are consistent with this observation, as risk
factors for CDI varied by time from HCT. Previously published studies of CDI in allogeneic and autologous HCT patients include a variety of follow-up periods, ranging from
30 days to 1 year.1,3,5,6,9-15,17,18,24 Kinnebrew et al6 found
that the majority of CDI cases occurred within a few days before or after HCT; however, the maximum follow-up time
was 35 days after transplant. Alonso et al10 found 81% of
CDI cases occurred within 30 days of autologous HCT. By
contrast, Willems et al,9 who evaluated CDI up to a year
post-HCT, found that the median time to CDI in their cohort
of allogeneic transplant patients was 25 days after HCT.
Chakrabarti and Alonso1,3 found median times to CDI of
38 and 33 days in their allogeneic HCT populations, respectively. Similarly, we found that 60% of the CDI cases occurred within 30 days of HCT, 18% occurred between days
31 and 99, and 22% of CDI cases occurred 100 or more days
after transplant. These results, along with those of previous
investigators, indicate CDI may be more common during
the late posttransplant period than has previously been recognized.1,3,9 Post-HCT surveillance for CDI should continue
beyond 30 days to fully understand the epidemiology of CDI
in HCT patients, and to facilitate interventions to prevent
CDI at different times posttransplant.
Few specific risk factors for CDI after allogeneic HCT
have been identified previously. This may be due to the universality of common risk factors for CDI in the preengraftment period, as suggested by our risk factor analysis
in the preengraftment period. Antimicrobial exposure is
widely considered the primary risk factor for CDI, but antimicrobial use in the preengraftment period was ubiquitous
in our allogeneic HCT population; 92% of CDI cases and
80% of noncases received an antimicrobial in the previous
30 days. Other medications or procedures that could predispose to CDI due to immune disruption, such as chemotherapy and immunosuppressive or steroid use, were also
nearly universal in this allogeneic HCT population. It is likely
these variables do increase patients’ risk of CDI, but all allogeneic HCT patients are exposed to these types of medications. Instead, our results indicate patients’ underlying
health status pretransplant may be the primary determinant
of individual risk for CDI in the preengraftment period.
The only independent predictor of CDI in the preengraftment
period we identified was having no underlying comorbid disease, which was protective of CDI. Although underlying
health status is not a modifiable risk factor, the presence of
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any comorbidity in allogeneic HCT recipients could be used
to target CDI prevention efforts. Receipt of myeloablative
conditioning pretransplant was marginally associated with
increased risk of CDI during the preengraftment period.
Kinnebrew et al6 also found that myeloablative conditioning
increased the risk of CDI. Myeloablative conditioning leads
to greater neutropenia and damage to the mucosa than
nonmyeloablative conditioning,25 resulting in increased susceptibility to other infections (leading to antimicrobial exposures)
and thus increased risk of CDI. Conversely, the mucositis caused
by myeloablative conditioning with resultant diarrhea may lead
to increased testing for C. difficile and detection of asymptomatic carriage in people with diarrhea from other causes.26
In contrast, we identified numerous risk factors for CDI
during the postengraftment period. The results of univariable
and multivariable analyses indicate the patients at highest
risk for CDI in the postengraftment period were those patients with prolonged immune disruption, as indicated by
prior infections, antimicrobial use, GVHD, and neutropenia.
Reducing these patients’ exposure to the inpatient healthcare
environment may decrease their risk of CDI.27 When this approach is impossible, careful assessment of the need for and
selection of antimicrobials and gastric acid suppressants
should be performed. That a much larger proportion of patients received antimicrobials than had an infection does indicate it may be possible to safely reduce or narrow the
spectrum of antimicrobial prescriptions for these patients.
These approaches have been somewhat successful at reducing rates of CDI in the general hospital population,28 although CDI remains a significant problem overall.29
The relationship between GVHD and CDI is complex and
deserves additional study. Available data suggest GVHD may
be both a risk factor and/or an outcome of CDI. In our study,
GVHD of any kind was associated with significantly increased risk of CDI in the postengraftment population. Gut
GVHD was marginally associated with increased risk of
CDI in univariable analysis, but the number of individuals
with gut GVHD was too small for the variable to be included
in the multivariable model. We have noted this relationship
between GVHD and increased risk of CDI previously at
our institution,19 as have Alonso et al and Chakrabarti
et al.1,3 Alonso found that CDI preceded GVHD in 86% of
patients, suggesting that GVHD may be an outcome of
CDI. In our analyses, we specifically examined GVHD with
onset before CDI and found GVHD to be a risk factor for
CDI in the postengraftment period. This apparent contradiction can be explained by the high degree of colinearity between the conditions, particularly in the case of gut GVHD
and CDI.25 Both gut GVHD and CDI may arise from loss
of a healthy gut microbiome. Jenq et al30 reported the loss
of gastrointestinal species diversity post-HCT in patients
with GVHD, both in a mouse model and in humans. This
loss of the normal gut microbiome has serious consequences
for patients. Taur et al31 reported increased post-HCT mortality in patients with low bacterial diversity in the gut
microbiome. The growing list of conditions and/or negative
patient outcomes arising from the disrupted microbiome
should give further impetus to efforts aimed at protecting patients’ normal flora, particularly through the judicious and
responsible use of antimicrobials.
Previous estimates of CDI incidence in the allogeneic HCT
population range from 12% to 30%.1,3-7,9 Our observed
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CDI incidence of 34% is slightly higher than previously published estimates, but this may be related to differences in
study design. Kinnebrew et al6 reported an incidence of
17% within 35 days posttransplant; our CDI incidence
within 30 days of transplant was comparable at 20%. In addition, because of our prospective study design and frequent
follow-up with participants, we were able to capture outpatient CDI cases among the allogeneic transplant population
that may have been missed if only inpatient data were used.
It is also possible that awareness of CDI among transplant
physicians has increased in recent years. In a previous analysis of CDI in allogeneic HCT recipients at our facility, 43% of
CDI cases were classified as having mild to moderate CDI
and 57% as having severe CDI.19 In the current study, using
the same modified CTCAE criteria for grading CDI severity,
73% of cases were classified as mild/moderate and only 27%
as severe. Heightened awareness of CDI may lead to increased diagnosis of mild CDI cases that would previously
have been undetected or earlier detection of CDI that would
have become severe if diagnosis was delayed; however, transplant patients are particularly prone to diarrhea due to multiple other causes (side effects of chemotherapy, radiation,
or other medications, GVHD, and so on), and the increase
in mild/moderate cases of CDI also may have led to increased
false-positive rates. Throughout the duration of the current
study and our previously published study, our clinical microbiology laboratory used toxin enzyme immunoassay assays
for C. difficile detection. Compared to PCR-based C. difficile detection, toxin enzyme immunoassay assays are less
likely to detect asymptomatic colonization, so detection of
asymptomatically colonized participants with diarrhea due
to unrelated causes should have been minimized.26 Analyses
of CDI incidence and outcomes in allogeneic transplant patients over time should take into consideration the diagnostic
tests used and how they may impact our understanding of
CDI epidemiology.26
There are several limitations to this study. We did not obtain stool samples from participants, so we were unable to
determine whether preexisting colonization was a risk factor
for CDI or may have led to detection of asymptomatic carriage in subjects with diarrhea due to other causes. Data on
asymptomatic colonization preallogeneic HCT combined
with detailed, prospective clinical data could resolve the
question of whether some participants with mild CDI are in
fact asymptomatically colonized and experiencing diarrhea
due to other causes. Finally, as with many studies of risk factors for CDI among allogeneic transplant recipients, our multivariable models were limited by small sample size. Allogeneic
HCT recipients are a fairly small patient population, and
larger, multicenter studies are needed to alleviate this problem.
Despite these limitations, ours is one of the larger analyses of
risk factors for CDI after allogeneic HCT. In addition, due to
differences in patient risk factors for infection during the pre
versus postengraftment period, we believe it is more appropriate to separate the pre and postengraftment periods to identify
risk factors for CDI.
Although most previous studies have focused on CDI in the
immediate posttransplant period, our study indicates that surveillance for CDI should continue into the postengraftment period as CDI continues to impact allogeneic HCT recipients’
health postengraftment. Clinicians should carefully weigh patients’ needs for antimicrobials with the potential long-term
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consequences of extensive antimicrobial use. Future studies,
particularly larger, multicenter studies, will help further elucidate the epidemiology of CDI in allogeneic HCT recipients
and may reveal novel strategies for CDI prevention in this
challenging patient population.
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